Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.58 |
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.41 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.39 |
| ▸ | LCK known ✓ | P06239 | 4/20 | 0.37 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.36 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.36 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997895 | 0.98 | GAA (0.59) | GAAPDK1PDK2PDK3PDK4 | |
| Hydrochloric Acid SCHEMBL839849 | 0.84 | GAA (0.42) | GAAALDH1A1HTR2AHTR2CMEN1 | |
| Hydrochloric Acid SCHEMBL1457203 | 0.84 | CYP3A4 (0.48) | GAAALDH1A1HTR2AHTR2BMEN1 | |
| SCHEMBL1289385 | 0.81 | GAA (0.44) | GAAALDH1A1HTR2AHTR2BMEN1 | |
| SCHEMBL1144086 | 0.81 | GAA (0.44) | GAAALDH1A1MEN1KMT2AMAPT | |
| Bromide SCHEMBL20984793 | 0.79 | GAA (0.42) | GAAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL11663384 | 0.77 | GAA (0.52) | GAAPDK1PDK2PDK3PDK4 | |
| Hydrochloric Acid SCHEMBL21357474 | 0.77 | GAA (0.41) | GAAALDH1A1HTR2AHTR2CMEN1 | |
| Hydrochloric Acid SCHEMBL9004815 | 0.76 | GAA (0.64) | GAAPDK1PDK2PDK3PDK4 | |
| SCHEMBL11405082 | 0.76 | GAA (0.55) | GAAPDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | GENASE THERAPEUTICS B V (NL) | 2025-12-25 | — | — | US | disclosed |
| EP-4469461-B1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B V (NL) | 2025-10-15 | — | — | EP | disclosed |
| EP-4469461-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | Genase Therapeutics B.V. (NL) | 2024-12-04 | — | — | EP | disclosed |
| CN-118946568-A | Tetrahydropyranopyrazole derivatives for the treatment of cancer and viral infections | 格纳赛治疗有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-111655680-B | Hormone receptor modulators for the treatment of metabolic mutations and fibrotic conditions and disorders | 阿德利克斯股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023144332-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B.V. (NL) | 2023-08-03 | — | — | WO | disclosed |
| EP-3681881-B1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX INC (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-111655680-A | Hormone receptor modulators for the treatment of metabolic mutations and fibrotic conditions and disorders | 阿德利克斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20180105509-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-04-19 | — | — | US | disclosed |
| EP-3286178-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | Almirall S.A. (ES) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016170009-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2016-10-27 | — | — | WO | disclosed |
| WO-1993024468-A1 | PYRIMIDINYL- AND TRIAZINYL- SALICYL- AND PICOLYLAMIDES AND THE USE, AS HERBICIDES, AND PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1993-12-09 | — | — | WO | disclosed |
| US-4575501-A | 2-Arylhydrazino-2-thiazolines, acyl derivatives of these compounds, 2-arylazo-2-thiazolines, preparation processes, and their use for combating ectoparasites and endoparasites | BAYER AKTIENGESELLSCHAFT (DE) | 1986-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105509-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN7A, SCN1A, SCN1B | GAA 3148/4885PTGS2 1317/4885HTR2A 1641/4885 |
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | CCNA1, KRAS, RSU1 | GAA 4077/4885PTGS2 2316/4885HTR2A 4497/4885 |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | NR1H4, FXR1, FXR2 | GAA 2703/4885PTGS2 1551/4885HTR2A 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.